Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

842 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Chen A, Roberts MS, Ward LM. Imel EA, et al. Among authors: roberts ms. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2990-2998. doi: 10.1210/clinem/dgad230. J Clin Endocrinol Metab. 2023. PMID: 37084401 Free PMC article.
X-Linked Hypophosphatemia: A New Era in Management.
Dahir K, Roberts MS, Krolczyk S, Simmons JH. Dahir K, et al. Among authors: roberts ms. J Endocr Soc. 2020 Oct 14;4(12):bvaa151. doi: 10.1210/jendso/bvaa151. eCollection 2020 Dec 1. J Endocr Soc. 2020. PMID: 33204932 Free PMC article. Review.
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Ward LM, et al. Among authors: roberts ms. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3241-e3253. doi: 10.1210/clinem/dgac296. J Clin Endocrinol Metab. 2022. PMID: 35533340 Free PMC article. Clinical Trial.
Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Jan de Beur SM, et al. Among authors: roberts ms. J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12. J Bone Miner Res. 2021. PMID: 33338281 Free PMC article. Clinical Trial.
Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, Martin JS, Carpenter TO. Jan de Beur SM, et al. Among authors: roberts ms. J Bone Miner Res. 2021 Dec;36(12):2455-2456. doi: 10.1002/jbmr.4317. Epub 2021 May 24. J Bone Miner Res. 2021. PMID: 34030212 Free PMC article. No abstract available.
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice.
Takahashi K, Rensing NR, Eultgen EM, Wang SH, Nelvagal HR, Le SQ, Roberts MS, Doray B, Han EB, Dickson PI, Wong M, Sands MS, Cooper JD. Takahashi K, et al. Among authors: roberts ms. bioRxiv [Preprint]. 2024 Mar 30:2024.03.29.587276. doi: 10.1101/2024.03.29.587276. bioRxiv. 2024. PMID: 38585903 Free PMC article. Preprint.
842 results